ArticleMolecular diversity2026
Design, synthesis, characterization and exploration of anti-HBV activity of matrine-adenine hybrids.
Article in Molecular diversity, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Hepatitis B virus (HBV) is a pathogen that often causes progressive liver disease, leading to acute, chronic hepatitis, cirrhosis, and ultimately the development of hepatocellular carcinoma. Although several antiviral drugs, including interferon alpha and nucleotide derivatives, have been approved for clinical treatment of HBV, key issues such as low to moderate efficacy, adverse side effects, and drug-resistant strains remain unresolved. In this study, based on the results of molecular docking experiments, twenty matrine-adenine hybrids were synthesized and their antiviral effect against HBV was evaluated. Biological evaluations revealed that these synthesized compounds showed significant anti-HBV activity. Of these, ten compounds significantly inhibited HBsAg secretion more than the positive control lamivudine (3TC). Remarkably, compounds 4c, 4d, and 4k showed the most significant inhibitory activity against HBV DNA replication with IC50 value of them were 12.51 ± 1.24 to 24.10 ± 0.56 μM, respectively. Which is stronger than that of substrate MMA (IC50 = 52.18 ± 3.14 μM). Structure–activity relationship (SAR) data concluded that with the growth of carbon chains in straight chain aliphatic hydrocarbons significantly enhanced anti-HBV activity, whereas cyclic aliphatic hydrocarbons substitutions contributed to moderate activity. Overall, this study identifies matrine–adenine hybrids as promising active compounds against HBV in vitro, providing a basis for further evaluation in more physiologically relevant models.
Indexed as
Identifiers
41966665What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.